Navigation Links
Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy

an organism.
Desensitization: conventional immunotherapy applied to treat allergies. Requires frequent injections (50-80 injections) of allergen under
the skin over several years.
Double-blind: a set-up often applied in clinical trials where neither the doctor nor the patient knows if placebo or the active drug
substance is applied.
Formulation: the method and process of selecting the components of a mixture. For drugs the term usually describes the way the drug is
prepared.
House dust mite allergen extract: a mixture of allergenic components from house dust mites.
Immunotherapeutic: a product aimed at activation of the immune system to modify and interfere with a certain disease process.
Median: a term used in the statistical analysis of a set of numbers; relates to or constitutes the middle value in a distribution. 50% of the
values are above and 50% below the median.
Monotherapy: treatment with one drug as opposed to combination therapy. Here the term refers to treatment with CYT003-QbG10 alone in
contrast to a regimen where CYT003-QbG10 is combined to an allergen extract (i.e. CYT005-AllQbG10).
Open-label: a set-up used in clinical trials where the doctor and the patient know what substance is administered; in contrast to e.g.
double-blind, placebo-controlled studies, where neither the doctor nor the patient have this knowledge.
Phase IIa: a clinical trial that examines a new drug candidate’s safety and exploratory efficacy and may include between 10 and 100
patients.
Placebo: dummy medical treatment.
QbG10: Cytos Biotechnology’s Immunodrug™ Qb filled with the immunostimulatory DNA sequence G10.
Randomized: random assignation of clinical trial participants to different treatment groups.
Th1 and Th2 type immune responses: describe T helper cell responses. T helper cells are a subset of T cells that secrete a variety of
m
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... -- A study using a relatively new imaging tool, ... the composition of carotid artery disease and has the ... disease, a leading cause of stroke. ... 2010 and May 2012, was featured in the June ... College of Cardiology (JACC) Cardiovascular Interventions. Interventional cardiologist ...
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... conducted by Dobson | DaVanzo & Associates found that ... (DME) may limit Medicare beneficiaries, access to home medical ... products that Medicare consumers rely on.   ... Americans who require oxygen equipment and therapy, mobility assistive ...
... Sept. 14, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... LLY ) and Alkermes, Inc. (Nasdaq: ... on BYETTA® (exenatide) injection and the investigational product BYDUREON™ ... the 46th Annual Meeting of the European Association for ...
Cached Medicine Technology:Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 2Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 3Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 4BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 2BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 3BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 4BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 5BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 6BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 7
(Date:10/1/2014)... modelling of the human eye, the brain of a ... and new technology, says a QUT leading robotics researcher. ... Engineering Faculty says the new study uses new computer ... high-density buildings or tunnels. , "This is a very ... putting two halves of a thing together because we,re ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 First Warning ... abnormal circadian cellular changes throughout the body, announced the ... to better address the company’s breadth of upcoming product ... breast cancer screening technology. , “Our initial focus will ... system which detects abnormal circadian cellular changes over time,” ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new NoteSwift™ 2.0 for ... is the bridge between the EHR and Dragon Medical ... information at the point of care. NoteSwift reduces the ... more than half – and virtually eliminates mouse clicks ... impedes EHR use according to the June 12, 2014 ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3
... said that it will announce a new brand of coffee ... 21 years of research, the CCRI expects to release the ... arabica variety is resistant to diseases such as leaf rust ... borer. ,CCRI officials said trials of the new ...
... again when she was pictured with baby bump . ... Travolta starrer Hairspray dressed in a figure-hugging black dress that ... ,Holmes sparked off rumours that she and hubby ... spotted with bump while visiting new best friends David and ...
... been ruled out of the entire Test series against India ... be out for four to six weeks, reports BBC . ... the hernia has come back and now it's all about ... Anderson, Stuart Broad and Chris Tremlett are vying for the ...
... Wednesday said the government was not averse to inviting the ... a mosquito borne fever in the state that has claimed ... expert teams have arrived in the state since the outbreak ... which have confirmed the fever as chikunguniya and nothing else, ...
... can overcome their problem by taking part in group ... ,The study also suggests that supplementing sildenafil, sold ... names, to group therapy can make the treatment more ... function relies on the coordination of psychological, endocrine, vascular, ...
... has reserved seats for students suffering from AIDS and cancer ... has reserved one seat for each of the fifty-six courses ... from cancer. ,However, the university feels that one ... time being, since it do not expects many patients queuing ...
Cached Medicine News:Health News:Harmison Ruled Out Off Test Series Due to Hernia 2
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip, 0.6 mm dual sideports, 20 gauge....
Nucleus chopper. For bimanual nucleus division....
Medicine Products: